Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW, 2007, Australia.
Centre for Inflammation, Centenary Institute, Sydney, NSW, 2050, Australia.
Inflammopharmacology. 2020 Aug;28(4):795-817. doi: 10.1007/s10787-020-00698-3. Epub 2020 Mar 18.
Respiratory disorders, especially non-communicable, chronic inflammatory diseases, are amongst the leading causes of mortality and morbidity worldwide. Respiratory diseases involve multiple pulmonary components, including airways and lungs that lead to their abnormal physiological functioning. Several signaling pathways have been reported to play an important role in the pathophysiology of respiratory diseases. These pathways, in addition, become the compounding factors contributing to the clinical outcomes in respiratory diseases. A range of signaling components such as Notch, Hedgehog, Wingless/Wnt, bone morphogenetic proteins, epidermal growth factor and fibroblast growth factor is primarily employed by these pathways in the eventual cascade of events. The different aberrations in such cell-signaling processes trigger the onset of respiratory diseases making the conventional therapeutic modalities ineffective. These challenges have prompted us to explore novel and effective approaches for the prevention and/or treatment of respiratory diseases. In this review, we have attempted to deliberate on the current literature describing the role of major cell signaling pathways in the pathogenesis of pulmonary diseases and discuss promising advances in the field of therapeutics that could lead to novel clinical therapies capable of preventing or reversing pulmonary vascular pathology in such patients.
呼吸系统疾病,尤其是非传染性、慢性炎症性疾病,是全球范围内导致死亡率和发病率的主要原因之一。呼吸系统疾病涉及多个肺部组成部分,包括气道和肺部,导致它们的生理功能异常。已经报道了几种信号通路在呼吸系统疾病的病理生理学中发挥重要作用。此外,这些通路成为导致呼吸系统疾病临床结果的复合因素。一系列信号成分,如 Notch、Hedgehog、Wingless/Wnt、骨形态发生蛋白、表皮生长因子和成纤维细胞生长因子,主要由这些通路在最终的级联反应中使用。这些细胞信号转导过程中的不同异常会引发呼吸系统疾病的发生,使传统的治疗方法无效。这些挑战促使我们探索预防和/或治疗呼吸系统疾病的新方法和有效方法。在这篇综述中,我们试图详细讨论描述主要细胞信号通路在肺部疾病发病机制中的作用的现有文献,并讨论在治疗领域的有前途的进展,这些进展可能导致新的临床疗法,能够预防或逆转此类患者的肺血管病理学。